Aristides Capital’s iRadimed IRMD Stock Holding History

Aristides Capital’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.1M	Buy	32,463 +2,380	+8%	+$217K	0.6%	42
2026 Q1	$2.9M	Buy	30,083 +2,349	+8%	+$235K	0.63%	39
2025 Q4	$2.7M	Buy	27,734 +1,309	+5%	+$112K	0.48%	44
2025 Q3	$1.88M	Sell	26,425 -3,500	-12%	-$233K	0.27%	59
2025 Q2	$1.79M	Hold	29,925	–	–	0.36%	46
2025 Q1	$1.57M	Hold	29,925	–	–	0.46%	48
2024 Q4	$1.65M	Buy	29,925 +11,452	+62%	+$603K	0.34%	48
2024 Q3	$929K	Hold	18,473	–	–	0.29%	68
2024 Q2	$812K	Hold	18,473	–	–	0.23%	88
2024 Q1	$813K	Buy	18,473 +8,600	+87%	+$380K	0.3%	78
2023 Q4	$469K	Buy	9,873 +673	+7%	+$28.3K	0.17%	94
2023 Q3	$408K	Buy	+9,200	New	+$427K	0.18%	88

Other funds holding IRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aristides Capital's IRMD Position: Q2 2026 in Review

Aristides Capital increased its iRadimed (IRMD) stake by 7.9% in Q2 2026, buying an estimated $217K and bringing the position to 32,463 shares worth $3.1M. The position accounts for 0.6% of the portfolio, ranked #42.

Aristides Capital first reported a position in IRMD in Q3 2023 and has held it in 12 quarters since. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

Aristides Capital held 32,463 shares of iRadimed worth $3.1M as of Q2 2026.
Aristides Capital bought 2,380 iRadimed shares in Q2 2026, an estimated $217K.
iRadimed made up 0.6% of Aristides Capital's portfolio in Q2 2026, its #42 holding.
Aristides Capital first reported a position in iRadimed in Q3 2023 and has held it in 12 quarters since.
214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Aristides Capital's 13F filing for Q2 2026, filed 13 Aug 2026.